April 16, 2014 — Researchers at Thomas Jefferson University have tested an experimental cancer vaccine in combination with radiation therapy in mice with colorectal cancer. In research published online in the International Journal of Radiation Oncology, they showed the vaccine was most effective when tumors were irradiated first and then vaccinated a week later.
April 16, 2014 — Visage Imaging announced it has released version 7.1.5 of the Visage 7 Enterprise Imaging Platform, including optimized navigation and tools, and significant speed enhancements to Visage 7’s performance with massive digital mammography and digital breast tomosynthesis (DBT) studies.
Navidea Biopharmaceuticals Inc. held an update meeting with the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for the pending Marketing Authorization Application (MAA) of Lymphoseek (technetium Tc 99m tilmanocept) Injection.
While most women understand the importance of health screenings, an estimated 72 million have missed or postponed a ...
Ion Beam Applications S.A. (IBA) announced the delivery of its 1,000th Blue Phantom² system. The device was delivered to the Centre de Radiothérapie des Ardennes, Charleville-Mézières, France.
April 15, 2014 — NEC Display Solutions of America announced U.S. Food and Drug Administration (FDA) 510(k) market clearance of the 30-inch MultiSync MD302C4 LCD, a widescreen display for diagnostic review applications in healthcare organizations.
SPONSORED CONTENT — Fujifilm’s latest CT technology brings exceptional image quality to a compact and user- and patient ...
April 15, 2014 — Mevion Medical Systems announced an agreement with Chiyoda Technol Corp. for the exclusive distribution of the Mevion S250 proton therapy system in the Japanese market.
Fujifilm’s APERTO Lucent is a 0.4T mid-field, open MRI system addressing today’s capability and image quality needs ...
April 15, 2014 — Shimadzu Medical Systems USA announced an agreement with Konica Minolta Medical Imaging to expand the availability of the AeroDR portable wireless solution to MobileArt portable X-ray systems.
aycan, in conjunction with its business partner, medQ,announced the availability of aycan workflow, a fully integrated radiology information system/picture archive and communication system (RIS/PACS) solution that provides a turnkey end-to-end digital imaging and patient management system.
The U.S. Food and Drug Administration (FDA) granted 510(k) market clearance for the GE Healthcare Revolution computed tomography (CT) system. The 256-slice CT system offers technology that provides excellent image quality and clinical capabilities through the convergence of coverage, spatial resolution and temporal resolution.
SPONSORED CONTENT — Fujifilm’s latest CT technology brings exceptional image quality to a compact and user- and patient ...
April 15, 2014 — VuComp Inc. announced it has released an updated version of its M-Vu Breast Density technology. The new M-Vu Breast Density 2.0 adds a critical dimension to the analysis of dense breast tissue. The VuComp density category, analogous to the BI-RADS breast density composition category, is now correlated to not only the amount, but also the distribution – the actual dispersion – of fibroglandular tissue.
April 11, 2014 — A University of Colorado Cancer Center study presented at the 2014 annual meeting of the American Association for Cancer Research (AACR) describes a novel method to "manipulate the lipid metabolism in the cancer cell to trick them to use more radiolabeled glucose, the basis of PET [positron emission tomography] scanning," according to Isabel Schlaepfer, Ph.D., investigator at the CU Cancer Center Department of Pharmacology and recipient of a 2014 Minority Scholar Award in Cancer Research from AACR.
April 11, 2014 — Calgary Scientific Inc. announced their latest Class II clearance from the U.S. Food and Drug Administration (FDA). Its enterprise image-viewing solution, ResolutionMD, is now cleared for diagnosis on mobile devices for all imaging modalities. This builds upon their previous clearances for diagnosis using web, iOS and Android devices.
SPONSORED CONTENT — EnsightTM 2.0 is the newest version of Enlitic’s data standardization software framework. Ensight is ...
April 11, 2014 — Medtronic announced CE mark and European launch of the Evera MRI SureScan implantable cardioverter-defibrillator (ICD) system, the first and only ICD system approved for magnetic resonance imaging (MRI) scans positioned on any region of the body. The Medtronic Evera MRI ICD is not approved in the United States.
Elekta, Royal Philips and University Medical Center (UMC) Utrecht (the Netherlands) announced that the initial components of the world's first high-field magnetic resonance imaging (MRI) guided radiation therapy system are being installed at UMC Utrecht.
SPONSORED CONTENT — EnsightTM 2.0 is the newest version of Enlitic’s data standardization software framework. Ensight is ...
The Ontario Association of Radiologists (OAR) strongly supports the Choosing Wisely Canada (CWC) campaign, launched by the Canadian Medical Assn.
April 10, 2014 — In a presentation exploring the promise of magnetic nanoparticle (mNP) hyperthermia in breast cancer treatment, Dartmouth researcher P. Jack Hoopes, DMV, Ph.D., co-director of Norris Cotton Cancer Center's Nanotechnology Working Group, reviewed preclinical studies conducted at Norris Cotton Cancer Center and discussed plans for early-phase clinical studies in humans at the annual meeting of the American Association for Cancer Research (AACR).
April 10, 2014 — Stephen Wiley of Terrell, Texas, is the first known patient to be treated for vocal cord cancer with the CyberKnife robotic radiosurgery system from Accuray, announced officials from the University of Texas Southwestern Medical Center.
April 10, 2014 — Fuel 3D Technologies Ltd. announced it has secured a £685,831 ($1.1 million) SBRI Healthcare development contract for the development of a 3-D medical imaging system.
April 10, 2014 — Dose-escalated intensity-modulated radiation therapy (IMRT) with use of a moderate hypofractionation regimen (72 Gy in 2.4 Gy fractions) can safely treat patients with localized prostate cancer with limited grade 2 or 3 late toxicity, according to a study published in the April 1, 2014, edition of the International Journal of Radiation Oncology ? Biology ? Physics (Red Journal), the official scientific journal of the American Society for Radiation Oncology (ASTRO).
Screening programs sometimes assume an almost mystical sense of destiny, as though the technology is fated for use. A lung cancer screening program in the 1950s through the 1970s was one of them. Chest X-rays and sputum cytology were used in the mistaken belief that they could spot lung cancer at a curable stage.